Clinical Trial Update: A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety and immunogenicity of a patient-derived autologous mRNA electroporated dendritic cell vaccine, given both intradermally an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Autologous mRNA Electroporated Dendritic Cell Vaccine (autologous mRNA electroporated dendritic cell vaccine)

Snippet

Sponsor: Bart Neyns | Conditions: Melanoma | Phase 1 | Status: COMPLETED